Pharmacological therapies for muscular dystrophies

Current Opinion in Neurology

Volumn 25, Issue 5, 2012, Pages 604-608

  Abdel Hamid, Hoda ^a   Clemens, Paula R ^b,c  

^a CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

muscular dystrophy; pharmacologic; therapy

Indexed keywords

AGENTS ACTING ON THE PERIPHERAL NERVOUS AND NEUROMUSCULAR SYSTEMS; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIINFLAMMATORY AGENT; DEFLAZACORT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DYSTROPHIN; MEXILETINE; NABUMETONE; PREDNISONE; SMT C1100; UNCLASSIFIED DRUG; UTROPHIN;

BECKER MUSCULAR DYSTROPHY; CORTICOSTEROID THERAPY; DRUG EFFICACY; DUCHENNE MUSCULAR DYSTROPHY; FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY; GENE MUTATION; GENE THERAPY; HUMAN; MUSCULAR DYSTROPHY; MYOTONIA; MYOTONIC DYSTROPHY; NONHUMAN; NONSENSE MUTATION; PATHOPHYSIOLOGY; PROTEIN EXPRESSION; REVIEW; UPREGULATION;

ADRENAL CORTEX HORMONES; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ANTI-ARRHYTHMIA AGENTS; ANTI-INFLAMMATORY AGENTS; BONE AND BONES; CODON, NONSENSE; HUMANS; MEXILETINE; MUSCULAR DYSTROPHIES; MUSCULAR DYSTROPHY, DUCHENNE; MUSCULAR DYSTROPHY, FACIOSCAPULOHUMERAL; MYOTONIC DYSTROPHY; UTROPHIN;

EID: 84866342485     PISSN: 13507540     EISSN: 14736551     Source Type: Journal    
DOI: 10.1097/WCO.0b013e328357f44c     Document Type: Review

References (41)

1. Engel AG, Ozawa E. Dystrophinopathies. In Engel AG, Franzini-Armstrong C, editors. Myology. 3rd ed. New York: McGraw-Hill; 2004. pp. 961-1025.
2. Griggs RC, Moxley RT III, Mendell JR, et al. Prednisone in Duchenne dystrophy. A randomized, controlled trial defining the time course and dose response. Clinical Investigation of Duchenne Dystrophy Group. Arch Neurol 1991; 48:383-388.
3. Bonifati MD, Ruzza G, Bonometto P, et al. A multicenter, double-blind, randomized trial of deflazacort versus prednisone in Duchenne muscular dystrophy. Muscle Nerve 2000; 23:1344-1347.
4. Matthews DJ, James KA, Miller LA, et al. Use of corticosteroids in a populationbased cohort of boys with Duchenne and Becker muscular dystrophy. J Child Neurol 2010; 25:1319-1324.
5. Escolar DM, Hache LP, Clemens PR, et al. Randomized, blinded trial of weekend vs. daily prednisone in Duchenne muscular dystrophy. Neurology 2011; 77:444-452.
6. Spurney CF. Cardiomyopathy of Duchenne muscular dystrophy: current understanding and future directions. Muscle Nerve 2011; 44:8-19.
7. Spurney CF, Sali A, Guerron AD, et al. Losartan decreases cardiac muscle fibrosis and improves cardiac function in dystrophin-deficient mdx mice. J Cardiovasc Pharmacol Ther 2011; 16:87-95.
8. Hor KN, Mazur W, Taylor MD, et al. Effects of steroids and angiotensin converting enzyme inhibition on circumferential strain in boys with Duchenne muscular dystrophy: a cross-sectional and longitudinal study utilizing cardiovascular magnetic resonance. J Cardiovasc Magn Reson 2011; 13:60.
9. D'Angelo MG, Gandossini S, Martinelli BF, et al. Nitric oxide donor and nonsteroidal anti-inflammatory drugs as a therapy for muscular dystrophies: evidence from a safety study with pilot efficacy measures in adult dystrophic patients. Pharmacol Res 2012; 65:472-479.
10. Khurana TS, Watkins SC, Chafey P, et al. Immunolocalization and developmental expression of dystrophin related protein in skeletal muscle. Neuromuscul Disord 1991; 1:185-194.
11. Gilbert R, Nalbantoglu J, Petrof BJ, et al. Adenovirus-mediated utrophin gene transfer mitigates the dystrophic phenotype of mdx mouse muscles. Human Gene Ther 1999; 10:1299-1310. (Pubitemid 29267585)
12. Tinsley J, Deconinck N, Fisher R, et al. Expression of full-length utrophin prevents muscular dystrophy in mdx mice. Nature Med 1998; 4:1441-1444. (Pubitemid 28553471)
13. Amenta AR, Yilmaz A, Bogdanovich S, et al. Biglycan recruits utrophin to the sarcolemma and counters dystrophic pathology in mdx mice. Proc Natl Acad Sci USA 2011; 108:762-767.
14. Chancellor DR, Davies KE, De MO, et al. Discovery of 2-arylbenzoxazoles as upregulators of utrophin production for the treatment of Duchenne muscular dystrophy. J Med Chem 2011; 54:3241-3250.
15. De MO, Dorgan CR, Johnson PD, et al. Discovery and SAR of 2-arylbenzotriazoles and 2-arylindazoles as potential treatments for Duchenne muscular dystrophy. Bioorg Med Chem Lett 2011; 21:4828-4831.
16. Tinsley JM, Fairclough RJ, Storer R, et al. Daily treatment with SMTC1100, a novel small molecule utrophin upregulator, dramatically reduces the dystrophic symptoms in the mdx mouse. PLoS One 2011; 6:e19189.
17. Moorwood C, Lozynska O, Suri N, et al. Drug discovery for Duchenne muscular dystrophy via utrophin promoter activation screening. PLoS One 2011; 6:e26169.
18. Basu U, Lozynska O, Moorwood C, et al. Translational regulation of utrophin by miRNAs. PLoS One 2011; 6:e29376.
19. artsma-Rus A, van Deutekom JC, Fokkema IF, et al. Entries in the Leiden Duchenne muscular dystrophy mutation database: an overview of mutation types and paradoxical cases that confirm the reading-frame rule. Muscle Nerve 2006; 34:135-144. (Pubitemid 44167796)
20. Malik V, Rodino-Klapac LR, Viollet L, et al. Gentamicin-induced readthrough of stop codons inDuchennemuscular dystrophy.AnnNeurol2010; 67:771-780.
21. Politano L, Nigro G, Nigro V, et al. Gentamicin administration in Duchenne patients with premature stop codon. Preliminary results. Acta Myol 2003; 22:15-21. (Pubitemid 36966404)
22. Wagner KR, Hamed S, Hadley DW, et al. Gentamicin treatment of Duchenne and Becker muscular dystrophy due to nonsense mutations. Ann Neurol 2001; 49:706-711. (Pubitemid 32530236)
23. Finkel RS. Read-through strategies for suppression of nonsense mutations in Duchenne/Becker muscular dystrophy: aminoglycosides and ataluren (PTC124). J Child Neurol 2010; 25:1158-1164.
24. McDonald DG, Kinali M, Gallagher AC, et al. Fracture prevalence in Duchenne muscular dystrophy. Dev Med Child Neurol 2002; 44:695-698. (Pubitemid 35230031)
25. Morgenroth VH, Hache LP, Clemens PR. Insights into bone health in Duchenne muscular dystrophy. BoneKEy Reports 2012; 1:9.
26. Siegel IM. Fractures of long bones in Duchenne muscular dystrophy. J Trauma 1977; 17:219-222. (Pubitemid 8096954)
27. Vestergaard P, Glerup H, Steffensen BF, et al. Fracture risk in patients with muscular dystrophy and spinal muscular atrophy. J Rehabil Med 2001; 33:150-155. (Pubitemid 32700475)
28. Bushby K, Finkel R, Birnkrant DJ, et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. Lancet Neurol 2010; 9:77-93.
29. Bushby K, Finkel R, Birnkrant DJ, et al. Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care. Lancet Neurol 2010; 9:177-189.
30. Bothwell JE, Gordon KE, Dooley JM, et al. Vertebral fractures in boys with Duchenne muscular dystrophy. Clin Pediatr (Phila) 2003; 42:353-356. (Pubitemid 36909149)
31. Talim B, Malaguti C, Gnudi S, et al. Vertebral compression in Duchenne muscular dystrophy following deflazacort. Neuromuscul Disord 2002; 12:294-295. (Pubitemid 34136914)
32. Whitaker M, Guo J, Kehoe T, Benson G. Bisphosphonates for osteoporosis: where do we go from here? N Engl J Med 2012; 366:2048-2051.
33. Sbrocchi AM, Rauch F, Jacob P, et al. The use of intravenous bisphosphonate therapy to treat vertebral fractures due to osteoporosis among boys with Duchenne muscular dystrophy. Osteoporos Int 2012. [Epub ahead of print]
34. Gordon KE, Dooley JM, Sheppard KM, et al. Impact of bisphosphonates on survival for patients with Duchenne muscular dystrophy. Pediatrics 2011; 127:e353-e358.
35. Hawker GA, Ridout R, Harris VA, et al. Alendronate in the treatment of low bone mass in steroid-treated boys with Duchennes muscular dystrophy. Arch Phys Med Rehabil 2005; 86:284-288. (Pubitemid 40215291)
36. Harper PS, Monckton DG. Myotonic dystrophy. In Engel AG, Franzini-Armstrong C, editors. Myology. 3rd ed. New York: McGraw-Hill; 2004. pp. 1039-1076.
37. Romeo V. Myotonic dystrophy type 1 or Steinert's disease. Adv Exp Med Biol 2012; 724:239-257.
38. Logigian EL, Martens WB, Moxley RT, et al. Mexiletine is an effective antimyotonia treatment in myotonic dystrophy type 1. Neurology 2010; 74:1441-1448.
39. Flanigan KM. Facioscapulohumeral muscular dystrophy and scapuloperoneal disorders. In Engel AG, Franzini-Armstrong C, editors. Myology. 3rd ed. New York: McGraw-Hill; 2004. pp. 1123-1133.
40. Sahenk Z, Mendell Jr. The muscular dystrophies: distinct pathogenic mechanisms invite novel therapeutic approaches. Curr Rheumatol Rep 2011; 13:199-207.
41. Nieto R, Raichle KA, Jensen MP, Miro J. Changes in pain-related beliefs, coping, and catastrophizing predict changes in pain intensity, pain interference, and psychological functioning in individuals with myotonic muscular dystrophy and facioscapulohumeral dystrophy. Clin J Pain 2012; 28:47-54.